Clinical trial of Kelisu combined nasal continuous positive airway pressure for neonatal respiratory ailure
10.13699/j.cnki.1001-6821.2018.09.005
- VernacularTitle:珂立苏联合鼻塞持续气道正压通气治疗新生儿呼吸衰竭的临床研究
- Author:
Jia-Wen DANG
1
;
Wen-Bin DONG
;
Xiao-Ping LEI
;
Na HE
;
Lin GUO
Author Information
1. 西南医科大学附属医院新生儿科
- Keywords:
neonatal respiratory failure;
nasal continuous positive airway pressure;
pulmonary surfactant;
arterial blood gas index
- From:
The Chinese Journal of Clinical Pharmacology
2018;34(9):1025-1028
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the effect of calf pulmonary surfactant (Kelisu) combined nasal continuous positive airway pressure (NCPAP) in the treatment of neonatal respiratory failure (NRF).Methods Forty-eight NRF in our hospital were selected,and divided into the control group (n =24) and the treatment group (n =24) according to random number table.Control group were given NCPAP therapy,treatment group were treated with Kelisu 70-100 mg · kg-1 combined NCPAP.After using Kelisu 0,6,12,24 h,the results of arterial blood gas analysis,respiratory function indexes,clinical effects and incidence of complications in the two groups were compared.The adverse drugs reaction (ADR)were investigated.Results After 12 h treatment,the level of PaO2 in treatment group with (75.7 ± 1.6) mmHg was higher than the control group with (70.8 ± 1.8) mmHg.The level of PaCO2 in treatment group with (51.2 ± 1.7) mmHg was lower than the control group with (53.8 ± 0.7) mmHg.The time of the oxygen curein in treatment group with(180.65 ± 21.64)h was shorter than the control group with (217.52 ±19.58)h.The incidence of ADR in treatment group with 16.7％ (4 cases/24 cases) was lower than the control group with 45.8％ (11 cases/24 cases).Camparison between control group and the treatment group on the factors,the differences were statistically significant(all P ＜ 0.05).Conclusion Endotracheal dripping of calf pulmonary surfactant combined with NCPAP is an effective treatment for NRF,and had good safety.
